U.S.-China trade battle, Takeda-Shire deal and China's new generics-favoring policies made our news this week. (Google)
The U.S. is planning additional tariffs against Chinese products that include biopharma materials. Analysts see more possibilities in Takeda's bid for Shire. China announced a package of policy to promote the substitution of originals for generics.
1. Biopharma caught in the crosshairs of U.S.-China trade tussle